<DOC>
	<DOCNO>NCT01257399</DOCNO>
	<brief_summary>To demonstrate import Mesalazine ( ASACOLÂ® ) non-inferior reference drug , market Mesalazine , regard primary endpoint ( rate non-emergence bloody stool ) , patient Ulcerative Colitis remission , treat 48 week .</brief_summary>
	<brief_title>Comparative Efficacy Safety Study Patients With Ulcerative Colitis Remission Phase</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patients ulcerative colitis remission define show Ulcerative ColitisDisease Activity Index ( UCDAI ) score 2 less bloody stool score 0 . Patients take adrenal corticosteroid ( oral formulation , enema , suppository , agent hemorrhoidal disease , injectable solution ) within 14 day start administration clinical study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>